CRMD CorMedix (CRMD) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001410098
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
98
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · no price filed
CorMedix insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for CorMedix Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Dec 9, 2025.
- The trade is 26.0% of the 38,473 shares held after it.
- 1 other insider sold within 30 days.
- 98 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Dillione Janet sold about $68.8K of CRMD on Jan 21, 2026; 1 other insider sold within 30 days and 98 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (3 buys, 1 sale), the last on Sep 12, 2025.
- +13.0% median (+12.2% mean) 90-day return after 3 previous buys.
- The trade is 49.7% of the 40,250 shares held after it.
- 3 other insiders sold within 30 days.
- 98 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director DUNTON ALAN W sold about $260.0K of CRMD on Dec 30, 2025; 3 other insiders sold within 30 days and 98 funds added in the latest 13F quarter.Context
- 7 earlier Form 4 trades (code P or S) here by this insider (6 buys, 1 sale), the last on Sep 12, 2025.
- +6.8% median (+8.9% mean) 90-day return after 6 previous buys.
- The trade is 5.9% of the 509,496 shares held after it.
- 3 other insiders sold within 30 days.
- 98 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Todisco Joseph sold about $360.0K of CRMD on Dec 18, 2025; 3 other insiders sold within 30 days and 98 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Dec 2, 2025.
- The trade is 70.1% of the 48,473 shares held after it.
- 3 other insiders sold within 30 days.
- 98 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Dillione Janet sold about $408.0K of CRMD on Dec 9, 2025; 3 other insiders sold within 30 days and 98 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 49.7% of the 80,498 shares held after it.
- 3 other insiders sold within 30 days.
- 98 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Lefkowitz Steven W sold about $475.2K of CRMD on Dec 9, 2025; 3 other insiders sold within 30 days and 98 funds added in the latest 13F quarter.35 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
98 funds bought in last quarter
more than 67% of Pharma & Biotech
Revenue
+617.0% year over year
more than 94% of Pharma & Biotech
Margin
52.3% net margin
more than 95% of Pharma & Biotech
Buybacks
$17.5M repurchased, FY to 2026-06-30
below 64% of Pharma & Biotech
Short interest
23.4% of the float short (float per yahoo 2026-10-26) · 18.9 days to cover · settled 2026-09-30
more than 93% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch CRMD
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-29.8%12M
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns CRMD: institutional holders (13F)
13F holdings, latest reported quarter
6,324,111 sh
$49.6M
6,274,076 sh
$49.3M
3,135,075 sh
$24.6M
2,316,845 sh
$18.2M
2,176,362 sh
$17.1M
Congress trades in CRMD
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
CRMD planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
CRMD mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
AUER GROWTH
$1.5M position · as of 2026-05-31
1.9%
Royce Capital Fund - Small-Cap Portfolio
$1.9M position · as of 2026-06-30
1.0%
Royce Small-Cap Value Fund
$1.2M position · as of 2026-06-30
1.0%
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF
$4.3M position · as of 2026-06-30
1.0%
PROFUND VP PHARMACEUTICALS
$112.5K position · as of 2026-06-30
1.0%
Direxion Daily Pharmaceutical & Medical Bull 3X Shares
$148.7K position · as of 2026-07-31
0.7%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 98 funds added last quarter. Each figure is a federal filing, dated the day it went public.
CRMD financials
Revenue growth
+617.0%
XBRL, annual
Net margin
52.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$462.2M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM CRMD
| FY Dec 2025 | $311.7M |
| FY Dec 2024 | n/a |
| FY Dec 2023 | $65.4K |
| FY Dec 2022 | $65.4K |
| FY Dec 2021 | $190.9K |
| Jun 2026 | $101.9M |
| Mar 2026 | $127.4M |
| Dec 2025 | $128.6M |
| Sep 2025 | $104.3M |
| Jun 2025 | $39.7M |
| Mar 2025 | $39.1M |
| Dec 2024 | $31.2M |
| Sep 2024 | $11.5M |
At each fiscal year end
Single quarter
Net margin, TTM
+40.5%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM CRMD
| FY Dec 2025 | +52.3% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | +25.5% |
| Mar 2026 | +30.3% |
| Dec 2025 | +10.9% |
| Sep 2025 | +104.1% |
| Jun 2025 | +49.9% |
| Mar 2025 | +52.8% |
| Dec 2024 | +43.1% |
| Sep 2024 | -24.2% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$250.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM CRMD
| FY Dec 2025 | $172.8M |
| FY Dec 2024 | -$50.7M |
| FY Dec 2023 | -$38.7M |
| FY Dec 2022 | -$24.6M |
| FY Dec 2021 | -$22.6M |
| Jun 2026 | $85.7M |
| Mar 2026 | $41.7M |
| Dec 2025 | $92.7M |
| Sep 2025 | $30.4M |
| Jun 2025 | $30.0M |
| Mar 2025 | $19.7M |
| Dec 2024 | -$5.6M |
| Sep 2024 | -$13.7M |
At each fiscal year end
Single quarter
Debt to equity
0.00x
long-term debt only, 2025-12-31 (6 months older than the period end); equity 2026-06-30
Debt to equity CRMD
| FY Dec 2025 | 0.00x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.00x |
| Mar 2026 | 0.00x |
| Dec 2025 | 0.00x |
| Sep 2025 | 0.39x |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
1,755.82x
TTM operating cash flow over long-term debt only, 2025-12-31 (6 months older than the period end)
Cash flow to debt CRMD
| FY Dec 2025 | 1,210.34x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 1,755.82x |
| Mar 2026 | 1,366.91x |
| Dec 2025 | 1,210.34x |
| Sep 2025 | 0.52x |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+54.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity CRMD
| FY Dec 2025 | +66.6% |
| FY Dec 2024 | -23.2% |
| FY Dec 2023 | -74.0% |
| FY Dec 2022 | -50.4% |
| FY Dec 2021 | -52.7% |
| Jun 2026 | +54.9% |
| Mar 2026 | +65.6% |
| Dec 2025 | +66.6% |
| Sep 2025 | +75.1% |
| Jun 2025 | +38.3% |
| Mar 2025 | +19.9% |
| Dec 2024 | -23.2% |
| Sep 2024 | -65.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+32.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets CRMD
| FY Dec 2025 | +34.5% |
| FY Dec 2024 | -17.8% |
| FY Dec 2023 | -64.3% |
| FY Dec 2022 | -45.4% |
| FY Dec 2021 | -47.7% |
| Jun 2026 | +32.4% |
| Mar 2026 | +37.5% |
| Dec 2025 | +34.5% |
| Sep 2025 | +39.2% |
| Jun 2025 | +33.0% |
| Mar 2025 | +15.8% |
| Dec 2024 | -17.8% |
| Sep 2024 | -54.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+150.3%
operating income after a 8.0% effective tax rate, over long-term debt only, 2025-12-31 (6 months older than the period end) plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital CRMD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | +150.3% |
| Mar 2026 | +123.1% |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+46.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed CRMD
| FY Dec 2025 | +40.8% |
| FY Dec 2024 | -28.7% |
| FY Dec 2023 | -77.5% |
| FY Dec 2022 | -51.3% |
| FY Dec 2021 | -54.1% |
| Jun 2026 | +46.3% |
| Mar 2026 | +48.3% |
| Dec 2025 | +40.8% |
| Sep 2025 | +30.7% |
| Jun 2025 | +36.9% |
| Mar 2025 | +16.7% |
| Dec 2024 | -28.7% |
| Sep 2024 | -71.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
3.87x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing CRMD
| FY Dec 2025 | 6.09x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 3.83x |
| Mar 2026 | 3.33x |
| Dec 2025 | 6.09x |
| Sep 2025 | 5.59x |
| Jun 2025 | 16.00x |
| Mar 2025 | 25.67x |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$362.3M
market value at close 2026-10-26 on 2026-08-10 shares, plus long-term debt only, 2025-12-31 (6 months older than the period end), minus cash 2026-06-30
Enterprise value CRMD
| FY Dec 2025 | $771.6M |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $359.3M |
| Mar 2026 | $358.8M |
| Dec 2025 | $771.6M |
| Sep 2025 | $964.2M |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+40.5%
TTM free cash flow over market value at close 2026-10-26
FCF yield CRMD
| FY Dec 2025 | +18.9% |
| FY Dec 2024 | -10.3% |
| FY Dec 2023 | -18.8% |
| FY Dec 2022 | -14.1% |
| FY Dec 2021 | -13.0% |
| Jun 2026 | +40.7% |
| Mar 2026 | +36.3% |
| Dec 2025 | +18.9% |
| Sep 2025 | +8.6% |
| Jun 2025 | +3.6% |
| Mar 2025 | -3.4% |
| Dec 2024 | -10.3% |
| Sep 2024 | -12.4% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.02x
P/E over trailing EPS growth of 166%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing CRMD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.02x |
| Mar 2026 | 0.00x |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $311.7M | $43.5M | n/a | $65.4K |
| Gross profit | $275.7M | $40.3M | n/a | $61.7K |
| Operating income | $150.1M | -$22.4M | -$49.0M | -$30.6M |
| Net income | $163.1M | -$17.9M | -$46.3M | -$29.7M |
| EPS (diluted) | 2.04 | -0.30 | -0.91 | -0.74 |
| Operating cash flow | $175.0M | -$50.6M | -$38.4M | -$24.4M |
| Cash | $144.8M | $40.7M | $43.6M | $43.1M |
| Long-term debt | $144.6K | n/a | n/a | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
CRMD Stock Sonar score 5/7 axes
Find similar shapesCompareCRMD ranks highest on profitability (97th percentile) and growth (94th), and lowest on risk and compliance (7th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
